Jasper Therapeutics Appoints New CEO, Executive Chair, and Schedules Clinical Data Webinar

summarizeSummary

Jasper Therapeutics announced a leadership transition, with Ron Martell stepping down as CEO and Jeet Mahal, the current COO, appointed as the new CEO and President. Thomas Wiggans was also appointed Executive Chair, and the company scheduled an investor webinar to present updated clinical data.

check_boxKey Events

• CEO and President Departure

  Ron Martell ceased serving as Chief Executive Officer and President, effective January 5, 2026. His departure constitutes a termination without Cause, entitling him to 18 months of base salary and COBRA premiums. He also automatically resigned from the Board.

• New CEO and President Appointment

  Jeet Mahal, the Company's current Chief Operating Officer, was appointed Chief Executive Officer and President, effective January 5, 2026. He will also serve as a Class III director on the Board. His annualized salary was increased to $600,000 with eligibility for an annual performance bonus of up to 50% of his base salary.

• Executive Chair Appointment

  Thomas G. Wiggans, the current Chairperson of the Board, was appointed as the Company's Executive Chair, effective January 5, 2026.

• Upcoming Clinical Data Presentation

  The Company will host an investor webinar on January 8, 2026, to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU.

auto_awesomeAnalysis

This filing signals a significant leadership transition and a strategic pivot for Jasper Therapeutics, a clinical-stage biotechnology company. The departure of the former CEO, while framed as a termination without cause, is immediately followed by the appointment of an internal successor with extensive industry experience, suggesting a focused approach to advancing its clinical pipeline. The elevation of the Chairperson to Executive Chair further strengthens the leadership structure. The simultaneous announcement of an investor webinar to present updated clinical data for briquilimab in CSU and CIndU provides a near-term catalyst and underscores the company's commitment to its lead programs. For a micro-cap biotech, these combined events are highly impactful, setting the stage for the company's next phase of clinical growth and potentially influencing investor sentiment significantly.